Cure8 research brief
People with IBD or their clinicians may see signals suggesting certain drugs are more often reported with ulcerative colitis; this study combines adverse‑event reports with gene‑expression comparisons to help prioritize which drug–mechanism links deserve focused clinical research.
Clinicians and researchers studying drug safety and mechanisms in IBD; patients on or considering biologic or immune‑targeting therapies who follow safety research.
The study used FAERS reports (2004–2024) limited to health‑professional reports and primary‑suspect drugs to identify medication-associated UC reporting signals.
It then scored directional transcriptional signatures from mouse antibody blockade experiments (IL‑17A/IL‑17RA, IL‑23p19, IL‑12/23p40) against two human UC mucosal cohorts to see whether blockade signatures resembled UC tissue.
The authors found several drugs with elevated reporting odds ratios for UC (example: secukinumab, isotretinoin) after applying exclusion criteria to reduce confounding by indication.
In transcriptomic comparisons, IL‑23 and IL‑12/23 blockade signatures tended to score lower in UC mucosa in both cohorts, while IL‑17 blockade signatures were not uniformly UC‑like across cohorts. The paper emphasizes that these results do not establish causality or incidence but help prioritize drugs and mechanisms for further clinical study.
FAERS is a spontaneous reporting database subject to reporting biases and cannot determine incidence or causation. Transcriptomic alignment between mouse experimental blockade and human UC tissue is suggestive but not definitive of mechanism.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A colon-targeted microcapsule could improve how drugs reach inflamed tissue in ulcerative colitis, potentially reducing stomach degradation and systemic side effects while increasing local effect.
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.
